New combo therapy aims to outsmart drug-resistant lung cancer
Disease control
Not yet recruiting
This study tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer whose disease has worsened after initial treatment. About 53 adults with EGFR-mutant NSCLC and additional PIK3CA/AKT1/PTEN gene changes will receive the two dr…
Phase: PHASE1, PHASE2 • Sponsor: Shanxi Province Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC